Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase. The BCYC average annual return since 2019 is shown above.
The Average Annual Return on the BCYC average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BCYC average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BCYC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|